Literature DB >> 17007818

Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis.

Mohanraj Rajesh1, Partha Mukhopadhyay, Sándor Bátkai, Grzegorz Godlewski, György Haskó, Lucas Liaudet, Pál Pacher.   

Abstract

Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme which plays an important role in regulating cell death and cellular responses to DNA repair. Pharmacological inhibitors of PARP are being considered as treatment for cancer both in monotherapy as well as in combination with chemotherapeutic agents and radiation, and were also reported to be protective against untoward effects exerted by certain anticancer drugs. Here we show that pharmacological inhibition of PARP with 3-aminobenzamide or PJ-34 dose-dependently reduces VEGF-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells in vitro. These results suggest that treatment with PARP inhibitors may exert additional benefits in various cancers and retinopathies by decreasing angiogenesis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17007818      PMCID： PMC1820627          DOI： 10.1016/j.bbrc.2006.09.049

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  31 in total

1.  Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells.

Authors:  Mohanraj Rajesh; Antonina Kolmakova; Subroto Chatterjee
Journal:  Circ Res       Date:  2005-09-08       Impact factor: 17.367

2.  Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.

Authors:  Pál Pacher; Lucas Liaudet; Jon G Mabley; Attila Cziráki; György Haskó; Csaba Szabó
Journal:  Int J Mol Med       Date:  2006-02       Impact factor: 4.101

3.  Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase.

Authors:  F G Soriano; P Pacher; J Mabley; L Liaudet; C Szabó
Journal:  Circ Res       Date:  2001-10-12       Impact factor: 17.367

Review 4.  Nitrosative stress and pharmacological modulation of heart failure.

Authors:  Pal Pacher; Richard Schulz; Lucas Liaudet; Csaba Szabó
Journal:  Trends Pharmacol Sci       Date:  2005-06       Impact factor: 14.819

5.  Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation.

Authors:  L Virág; P Jagtap; E Szabó; J G Mabley; L Liaudet; A Marton; D G Hoyt; K G Murthy; A L Salzman; G J Southan; C Szabó
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

6.  Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.

Authors:  L Tentori; I Portarena; E Bonmassar; G Graziani
Journal:  Cell Death Differ       Date:  2001-05       Impact factor: 15.828

7.  Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo.

Authors:  Maria Grazia Cattaneo; Sandra Pola; Pierangelo Francescato; Francesco Chillemi; Lucia Maria Vicentini
Journal:  Exp Cell Res       Date:  2003-02-15       Impact factor: 3.905

8.  Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.

Authors:  L Tentori; I Portarena; P Vernole; P De Fabritiis; R Madaio; A Balduzzi; R Roy; E Bonmassar; G Graziani
Journal:  Cancer Chemother Pharmacol       Date:  2001-04       Impact factor: 3.333

9.  Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

Authors:  Christopher R Calabrese; Michael A Batey; Huw D Thomas; Barbara W Durkacz; Lan-Zhen Wang; Suzanne Kyle; Donald Skalitzky; Janke Li; Catherine Zhang; Theodore Boritzki; Karen Maegley; Alan H Calvert; Zdenek Hostomsky; David R Newell; Nicola J Curtin
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

10.  The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.

Authors:  Joseph A De Soto; Xianyan Wang; Yohei Tominaga; Rui-Hong Wang; Liu Cao; Wenhui Qiao; Cuiling Li; Xiaoling Xu; Amanda P Skoumbourdis; Sheila A Prindiville; Craig J Thomas; Chu-Xia Deng
Journal:  Int J Biol Sci       Date:  2006-06-10       Impact factor: 6.580
View more
  28 in total

1.  Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury.

Authors:  Partha Mukhopadhyay; Béla Horváth; Malek Kechrid; Galin Tanchian; Mohanraj Rajesh; Amarjit S Naura; A Hamid Boulares; Pál Pacher
Journal:  Free Radic Biol Med       Date:  2011-08-17       Impact factor: 7.376

2.  Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.

Authors:  Sharareh Siamakpour-Reihani; Kouros Owzar; Chen Jiang; Peter M Scarbrough; Oana I Craciunescu; Janet K Horton; Holly K Dressman; Kimberly L Blackwell; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2015-03-26       Impact factor: 3.914

Review 3.  PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

Authors:  Nilufer Jasmine Selimah Fauzee; Juan Pan; Ya-lan Wang
Journal:  Pathol Oncol Res       Date:  2010-04-12       Impact factor: 3.201

4.  Poly(ADP-ribose)polymerase inhibition decreases angiogenesis.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Grzegorz Godlewski; Sándor Bátkai; György Haskó; Lucas Liaudet; Pál Pacher
Journal:  Biochem Biophys Res Commun       Date:  2006-10-09       Impact factor: 3.575

Review 5.  PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

Authors:  Susana Banerjee; Stan Kaye
Journal:  Curr Oncol Rep       Date:  2011-12       Impact factor: 5.075

6.  CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

Authors:  M Rajesh; P Mukhopadhyay; G Haskó; J W Huffman; K Mackie; P Pacher
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

7.  Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; György Haskó; Pál Pacher
Journal:  Biochem Biophys Res Commun       Date:  2008-11-06       Impact factor: 3.575

8.  PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.

Authors:  Irina G Obrosova; Weizheng Xu; Valeriy V Lyzogubov; Olga Ilnytska; Nazar Mashtalir; Igor Vareniuk; Ivan A Pavlov; Jie Zhang; Barbara Slusher; Viktor R Drel
Journal:  Free Radic Biol Med       Date:  2007-10-03       Impact factor: 7.376

Review 9.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.

Authors:  Pal Pacher; Csaba Szabo
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 10.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.